Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: Reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies

Clinical and Experimental Allergy

Volumn 33, Issue 9, 2003, Pages 1198-1208

  Mothes, N ^a   Heinzkill, M ^a,b   Drachenberg, K J ^a,b   Sperr, W R ^c   Krauth, M T ^c   Majlesi, Y ^c   Semper, H ^c   Valent, P ^c   Niederberger, V ^a   Kraft, D ^a   Valenta, Rudolf ^a,c  

^a UNIVERSITY OF VIENNA   (Austria)

^b Bencard Allergie GmbH   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Blocking antibodies; Immunotherapy; Recombinant grass pollen allergens

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; PHOSPHORYL LIPID A; PLACEBO; VACCINE;

ANTIBODY PRODUCTION; ARTICLE; BASOPHIL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; GRASS POLLEN; HISTAMINE RELEASE; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOTHERAPY; POLLEN ALLERGY; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; BASOPHILS; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; HISTAMINE RELEASE; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOTHERAPY; LIPID A; PHLEUM; POLLEN; SEASONS; VACCINES;

EID: 0043264799     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2003.01699.x     Document Type: Article

References (35)

1. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102:558-62.
2. Noon L. Prophylactic inoculation against hay fever. Lancet 1911; 1:1572-3.
3. Durham SR, Till SJ. Immunological changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998; 102:157-64.
4. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002; 2:446-53.
5. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997; 18:263-6.
6. Ebner C. Immunological mechanisms operative in allergen-specific immunotherapy. Int Arch Allergy Immunol 1999; 119:1-5.
7. Durham SR, Kay AB, Hamid Q. Changes in allergic inflammation associated with successful immunotherapy. Int Arch Allergy Immunol 1995; 107:282-4.
8. Hsu CH, Chua KY, Tao MH et al. Immuno-prophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat Med 1996; 2:540-4.
9. van Uden J, Raz E. Immunostimulatory DNA and applications to allergic disease. J Allergy Clin Immunol 1999; 104:902-10.
10. Sehra S, Chugh L, Gangal SV. Polarized Th1 responses by liposome-entrapped allergen and its potential in immunotherapy of allergic disorders. Clin Exp Allergy 1998; 28:1530-7.
11. Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. In: Powell MF, Newman MJ, eds. Vaccine design: the subunit and adjuvant approach. New York: Plenum Press, 1995:495-524.
12. Wheeler AW, Marshall JS, Ulrich JT. A Th1-inducing adjuvant, MPL® enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int Arch Allergy Immunol 2001; 126:135-9.
13. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001; 56:498-505.
14. Vrtala S, Susani M, Sperr WR et al. Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Ph1 p 1, Ph1 p 2, Ph1 p 5). J Allergy Clin Immunol 1996; 97:781-7.
15. Moran DM, Wheeler AW, Overell BG, Woroniecki SR. Chemical modification of crude timothy grass pollen extract. III. The effect of glutaraldehyde-induced aggregation on antigenic and immunogenic properties. Int Arch Allergy Appl Immunol 1977; 55:315-321.
16. Valent P, Besemer J, Muhm M et al. Interleukin-3 activates human blood basophils via high affinity binding sites. Proc Natl Acad Sci USA 1989; 86:5542-6.
17. Ball T, Fuchs T, Sperr WR et al. B cell epitopes of the major timothy grass pollen allergen, rPh1 p 1, revealed by gene fragmentation as candidates for immunotherapy. FASEB J 1999; 13:1277-90.
18. Thoelen S. An overview on a novel adjuvanted prophylactic hepatitis B vaccine. Acta Gastrenterol Belg 2000; 63:185-6.
19. Thoelen S, Van Damme P, Mathei C et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 1998; 16:708-14.
20. Heppner DG, Gordon DM, Gross M et al. Safety immunogenicitiy and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. J Infect Dis 1996; 174:361-6.
21. Henderson LL, Larson JB, Gleich GJ. Maximal rise in IgE antibody following ragweed pollination season. J Allergy Clin Immunol 1975; 55:10-5.
22. Clinton PM, Kemeny DM, Youlten LJ, Lessof MH. Histamine release from peripheral blood leukocytes with purified bee venom allergens: effect of hyperimmune beekeeper plasma. Int Arch Allergy Immunol 1989; 89:43-8.
23. Linhart B, Jahn-Schmid B, Verdino P et al. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity: FASEB J. (21 June, 2002) 10.1096/fj.01-1012fje.
24. Djurup R, Malling HJ. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin Allergy 1987; 17:459-68.
25. Boluda L, Fernandez-Caldas E, Berrens L. The role of IgG in Type I allergy: an unsolved problem. J Invest Allergol Clin Immunol 1997; 7:205-10.
26. Denepoux S, Eibensteiner PB, Steinberger P et al. Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction. FEBS Lett 2000; 465:39-46.
27. 1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. J Immunol 1998; 160:6137-44.
28. Vrtala S, Sperr WR, Reimitzer I et al. cDNA cloning of a major allergen from timothy grass (Phleum pratense) pollen; characterization of the recombinant Phl p V allergen. J Immunol 1993; 151:4773-81.
29. Laffer S, Spitzauer S, Susani M et al. Comparison of recombinant timothy grass pollen allergens with natural extract for diagnosis of grass pollen allergy in different populations. J Allergy Clin Immunol 1996; 98:652-8.
30. Bufe A, Gehlhar K, Schramm G, Schlaak M, Becker WM. Allergenic activity of a major grass pcllen allergen is elevated in the presence of nasal secretion. Am J Respir Crit Care Med 1998; 157:1269-76.
31. Flicker S, Vrtala S, Steinberger P et al. A human monoclonal IgE antibody defines a highly allergenic fragment of the major timothy grass pollen allergen, Ph1 p 5: molecular, immunological and structural characterization of the epitope-containing domain. J Immunol 2000; 165:3849-59.
32. + T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999; 163:2944-52.
33. 2. J Immunol 1994; 153:4948-58.
34. 2 deficiency associated with defects in production of interferon-γ. Scand J Immunol 1995; 41:1304.
35. 2 humoral response in infants is not due to intrinsic T or B cell defects. Int Immunol 1996; 8:1495-502.